Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat

Neurogastroenterology and Motility

Volumn 21, Issue 9, 2009, Pages

  Bucinskaite, V ^a   Tolessa, T ^a,b,c   Pedersen, J ^d   Rydqvist, B ^a   Zerihun, L ^c   Holst, J J ^d   Hellstrom P M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ADDIS ABABA UNIVERSITY   (Ethiopia)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Exendin; Glucagon like peptides; Peptide hormones; Vagal afferents

Indexed keywords

AMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMORECEPTOR; CONTROLLED STUDY; DESENSITIZATION; ELECTROPHYSIOLOGY; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRACT FUNCTION; GENE EXPRESSION; MALE; NODOSE GANGLION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR GENE; RECEPTOR INTRINSIC ACTIVITY; REPEAT PROCEDURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSORY NERVE; SENSORY NERVE CELL; SENSORY STIMULATION; STOMACH DISTENSION; STOMACH INNERVATION; VAGUS NERVE; VAGUS NERVE STIMULATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HYDROCHLORIC ACID; INJECTIONS, INTRAVENOUS; MALE; NEURONS, AFFERENT; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; STOMACH; VAGUS NERVE;

EID: 67449169287     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2009.01317.x     Document Type: Article

References (41)

1. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels 2002 8 : 179 88.
2. Creutzfeldt W. The incretin concept today. Diabetologia 1979 16 : 75 85.
3. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987 2 : 1300 3.
4. Eissele R, Göke R, Weichhardt U, Fehmann HC, Arnold R, Göke B. Glucagon-like peptide-I cells in the gastrointestinal tract and pancreas of rat, pig, and man. Eur J Clin Invest 1992 22 : 283 91.
5. Edwards CM, Todd JF, Mahmoudi M et al. Glucagon-like peptide-1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999 48 : 86 93.
6. Holst JJ. Enteroglucagon. Annu Rev Physiol 1997 59 : 257 71.
7. Bell G, Sanchez-Pescador R, Laybourn P, Najarian R. Exon duplication and divergence in the human preproglucagon gene. Nature 1993 304 : 368 71.
8. Drucker DJ, Asa S. Glucagon gene expression in vertebrate brain. J Biol Chem 1988 263 : 13475 8.
9. Jin SL, Han VK, Simmons JG, Towle AC, Lauder JM, Lund PK. Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 1988 271 : 519 32.
10. Ørskov C, Holst JJ, Poulsen SS, Kirkegaard P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987 30 : 874 81.
11. Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent releasing polypeptide. Endocr Rev 1995 16 : 390 410.
12. Hellström PM, Näslund E. Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1. Physiol Behav 2001 74 : 735 41.
13. Jang HJ, Kokrashvili Z, Theodorakis MJ et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci U S A 2007 104 : 15069 74.
14. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993 38 : 665 73.
15. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellström PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998 43 : 2284 90.
16. Schirra J, Houck PU, Wank P et al. Differential effects of subcutaneous GLP-1 on gastric emptying, gastroduodenal motility, and pancreatic function in man. Proc Assoc Am Physicians 1997 109 : 84 97.
17. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellström PM. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest 1998 102 : 764 74.
18. Schirra J, Houck PU, Wank R, Arnold B, Göke R, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000 46 : 622 31.
19. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001 50 : 2530 9.
20. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995 7 : 2294 300.
21. Uttenthal LO, Toledano A, Blázquez E. Autoradiographic localization of receptors for glucagon-like peptide-1(7-36)amide in rat brain. Neuropeptides 1992 21 : 143 6.
22. Tang-Christensen M, Larsen PJ, Göke R et al. Central administration of GLP-1-(7-36)amide inhibits food and water intake in rats. Am J Physiol 1996 271 : R848 56.
23. Nakagawa A, Satake H, Nakabayashi H et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004 110 : 36 43.
24. Dubé PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol 2007 293 : E460 5.
25. Bozkurt A, Näslund E, Holst JJ, Hellström PM. GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat. Regul Pept 2002 107 : 129 35.
26. Nelson DW, Sharp JW, Brownfield MS, Raybould HE, Ney DM. Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. Endocrinology 2007 148 : 1954 62.
27. A receptors. Br J Pharmacol 2000 129 : 1649 54.
28. Rozen S, Skaletsky HJ. Bioinformatics. Methods and protocols. In : Misener S, Krawetz S, eds. Methods in Molecular Biology. Totowa, NJ, USA : Humana Press, 2000 : 365 86.
29. Holst JJ. Extrapancreatic glucagons. Digestion 1978 17 : 168 90.
30. Näslund E, Skogar S, Efendic S, Hellström PM. Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin. Regul Pept 2002 106 : 89 95.
31. Blackshaw LA, Grundy D, Scratcherd T. Involvement of gastrointestinal mechano- and intestinal chemoreceptors in vagal reflexes: an electrophysiological study. J Auton Nerv Syst 1987 18 : 225 34.
32. Vrang N, Phifer CB, Corkern MM, Berthoud H-R. Gastric distension induces c-Fos in medullary GLP1-2 containing neurons. Am J Physiol 2003 285 : R470 8.
33. Näslund E, Hellström PM. Appetite signaling: from gut peptides and enteric nerves to brain. Physiol Behav 2007 92 : 256 62.
34. 2 +in rat nodose ganglion neurons. Auton Neurosci 2002 102 : 39 44.
35. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007 87 : 1409 39.
36. Bloom SR. Gut hormones in adaptation. Gut 1987 28 (Suppl. 31 5.
37. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996 93 : 7911 6.
38. Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 1998 275 : G911 21.
39. Schmidt PT, Näslund E, Grybäck P et al. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 2003 116 : 21 5.
40. Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 2004 39 : 353 8.
41. Hellström PM, Hein J, Bytzer P, Björnsson E, Kristensen J, Schambye H. Clinical trial: The GLP-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomised, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009 29 : 198 206.